非奈利酮治疗肾小球疾病所致慢性肾脏病:一项随机临床试验
该研究为一项3期随机双盲安慰剂对照试验的预设探索性亚组分析,纳入903例研究者报告的肾小球疾病患者。非奈利酮组eGFR下降斜率较安慰剂组减缓(差异0.73 mL/min/1.73 m2/年,95%CI 0.22-1.24),12个月白蛋白尿降低42%(95%CI 35%-48%),肾衰竭或eGFR持续下降40%以上的风险降低(HR 0.74,95%CI 0.57-0.97)。
要点
- 非奈利酮减缓肾小球疾病患者eGFR下降。
- 非奈利酮显著降低白蛋白尿。
- 非奈利酮降低肾衰竭或eGFR大幅下降风险。
核心结论
- 在肾小球疾病患者中,非奈利酮治疗减缓肾功能下降、降低白蛋白尿并降低肾衰竭或肾功能大幅丧失的风险。
研究设计与样本
- 一项3期随机双盲安慰剂对照试验的预设探索性亚组分析,在24个国家和地区开展。
- 纳入903例研究者报告的肾小球疾病患者,非奈利酮10 mg或20 mg每日一次口服(n=446)对比匹配安慰剂(n=457)。
主要发现
- 至32个月的总eGFR斜率:非奈利酮组-3.50 mL/min/1.73 m2/年,安慰剂组-4.23 mL/min/1.73 m2/年,差异0.73 mL/min/1.73 m2/年(95%CI 0.22-1.24)。
- 非奈利酮在12个月时降低白蛋白尿42%(95%CI 35%-48%)。
- 肾衰竭或eGFR持续下降40%以上的复合结局:非奈利酮组7.42事件/100患者年,安慰剂组9.60事件/100患者年,HR 0.74(95%CI 0.57-0.97)。
临床怎么用
- 对于肾小球疾病所致CKD患者,可考虑使用非奈利酮以延缓肾功能下降和降低蛋白尿。
局限性
- 本研究为探索性亚组分析,结果需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Glomerular diseases are a leading cause of chronic kidney disease (CKD) and kidney failure. Finerenone, a nonsteroidal mineralocorticoid receptor antagonist, reduces the risk of kidney function loss in CKD, but its effects in individuals with CKD due to glomerular diseases are uncertain. OBJECTIVES: To evaluate the efficacy and safety of finerenone in patients with glomerular diseases. DESIGN, SETTING, AND PARTICIPANTS: Prespecified exploratory subgroup analysis of a phase 3, randomized, double-blind, placebo-controlled trial conducted across 24 countries and regions, focusing on participants with an investigator-reported glomerular disease diagnosis. The overall trial enrolled adults with nondiabetic CKD and an estimated glomerular filtration rate (eGFR) of either (1) at least 25 to less than 60 mL/min/1.73 m2 and urinary albumin to creatinine ratio of at least 200 mg/g to less than 500 mg/g or (2) an eGFR of at least 25 to less than 90 mL/min/1.73 m2 and urinary albumin to creatinine ratio of at least 500 mg/g to less than 3500 mg/g. INTERVENTION: Finerenone 10 mg or 20 mg taken orally once daily (n = 446) vs matching placebo (n = 457). MAIN OUTCOMES AND MEASURES: Annualized rate of eGFR decline (total eGFR slope) from baseline to month 32 (primary outcome of the main trial); percent change in albuminuria to 12 months; and a composite outcome of kidney failure or sustained 40% or more decline in eGFR (prespecified exploratory outcomes). RESULTS: Of 1584 participants, 903 (57.0%) had investigator-reported glomerular disease, including 416 (46.1%) with immunoglobulin A nephropathy, 215 (23.8%) with focal segmental glomerulosclerosis, and 90 (10.0%) with membranous nephropathy. Participants with glomerular disease (mean [SD] age, 51.1 [13.6] years; 362 female [40.1%]; 558 Asian [61.9%]) had a mean eGFR of 48.8 mL/min/1.73 m2 and median urinary albumin to creatinine ratio of 839.6 mg/g. The total eGFR slope up to 32 months was -3.50 mL/min/1.73 m2 per year with finerenone and -4.23 mL/min/1.73 m2 per year with placebo (0.73 mL/min/1.73 m2 per year difference; 95% CI, 0.22-1.24). Finerenone reduced albuminuria at month 12 by 42% (95% CI, 35%-48%) and lowered the risk of kidney failure or 40% or more eGFR decline (7.42 vs 9.60 events per 100 patient-years; hazard ratio, 0.74; 95% CI, 0.57-0.97). CONCLUSIONS AND RELEVANCE: In this exploratory analysis, treatment with finerenone slowed kidney function decline, reduced albuminuria, and lowered the risk of kidney failure or substantial loss of kidney function in patients with glomerular diseases. These findings suggest an important role for finerenone in preserving kidney function in this population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05047263.
引用
- Neuen BL, Perkovic V, Agarwal R, et al. Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases: A Randomized Clinical Trial. JAMA. 2026. PMID: 42246414. doi:10.1001/jama.2026.9923
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。